AstraZeneca Results Presentation Deck
$bn
22.9
Net debt
end 2022
$12.7bn
Cash Flow, Net Debt and 2023 Financial Guidance
Continued EBITDA improvement
8.0
CFO
Net Debt bridge
0.8
Capex
3.3
4.5
Deal payments Dividend
and receipts(¹)
Adjusted EBITDA²-
Net Debt/EBITDA: 1.7x
CEO Opening Remarks
0.2
Other
23.4
Financial Results
Net debt end
Sep 2023
$14.0bn
Oncology
BioPharmaceuticals
Rare Disease
Total Revenue
Updated 2023 Guidance (CER)
Mid single-digit % increase
(previously low-to-mid single-digit % increase)
Total Revenue excluding COVID-19 medicines
Low-teens % increase
(previously low double-digit % increase)
CEO Closing Remarks
Core EPS
Low double-digit to low-teens % increase
(previously high single-digit to low double-digit % increase)
Low single digit adverse FX impact on Total Revenue
Mid single-digit adverse FX impact on Core EPS³
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma
share purchase liability and acquisitions of subsidiaries, net of cash acquired. 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $387m (FY 2022: $3,484m).
B
11 AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. Assuming average September 2023 foreign exchange rates for October to December
2023. EBITDA = earnings before interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities; CER = constant exchange rates; EPS = earnings per share.View entire presentation